Which of the following is a new drug recently approved for treatment of neovascular age related macular degeneration?
*Brolucizumab is a monoclonal antibody against VEGF. *It is recently approved for wet (neovascular) age related macular degeneration.* Istradefylline is adenosine A2 receptor antagonist. It is approved for off episodes in Parkinsonism* Lefamulin is a new antimicrobial that acts by inhibiting protein synthesis. It is approved for community acquired bacterial pneumonia.
Brolucizumab
Istradefylline
Lefamulin
Upadacitinib
Targeted Anticancer Drugs and Immunosuppressants